Blis Technologies Limited — Investor Relations & Filings

Blis Technologies Limited specializes in the research, development, and commercialization of advanced probiotic strains specifically designed for oral health. The company focuses on the oral microbiome, utilizing patented strains of Streptococcus salivarius, most notably BLIS K12 and BLIS M18. These probiotics are engineered to support the natural immune defenses of the mouth and throat, providing protection against common bacterial infections and promoting healthy teeth and gums. The company's product portfolio includes formulations for throat health, immune support, and dental hygiene, targeting both consumer retail and ingredient supply markets. By leveraging proprietary fermentation and stabilization technologies, the company delivers clinically backed solutions that aim to maintain a healthy microbial balance in the oral cavity.